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Purpose: To describe the development and psychometric testing of a new questionnaire to
measure the burden of immunoglobulin treatment (Ig) from the perspective of patients with
primary immunodeficiencies (PID).
Patients and Methods: An online, cross-sectional survey was administered to PID patients
across 10 countries (nine European and Canada) who were receiving either intravenous (IVIg) or
subcutaneous (SCIg) immunoglobulin therapy. The range and distribution of the responses (ie,
levels of missing data, floor and ceiling effects), exploratory factor analysis (using factor loadings
of 0.4 or greater) and measures of internal consistency reliability (ie, Cronbach’s alpha coefficient,
inter-item and item-total correlations) were used to identify the domain and item pool.
Results: In total, 472 patients completed the questionnaire, of which 395 were included in
the analysis (32% underwent IVIg and 67% underwent SCIg). The final instrument contained
34 items across eight domains of treatment burden (time, organisation and planning, leisure
and social, interpersonal relationships, employment and education, travel, consequences of
treatment and emotional) and an additional Ig treatment burden global question at the end of
the measure. All the scales achieved good internal reliability (Cronbach’s alpha coefficient
ranged from 0.70 to 0.85) and, with the exception of one item exceeded the minimum
threshold of 0.35 for item-total correlations. Treatment burden was lower than anticipated
across the different treatment routes and countries, although overall was more burdensome
for patients undergoing IVIg compared to SCIg treatment.
Conclusion: The IgBoT-35 appears to be a reliable, patient-generated questionnaire and
may help to identify more individualised and preferred therapies for the PID patient when
used in clinical practice. A new survey with a sample of US patients is currently being
undertaken to further establish its validity and conceptual model. The overall Ig burden of
treatment scores appeared to be low. PID patient preferences are important to guide treatment
decisions and ensuring patients receive the right treatment at the right time.
Keywords: intravenous immunoglobulins, subcutaneous immunoglobulins, primary
immunodeficiency, treatment burden, patient preference, quality of life
Plain Language Summary
In an age where minimally disruptive medicine is a key goal of healthcare delivery, it is
important to identify any potential treatment burden from the patient’s perspective. The
IgBoT-35 is a new questionnaire for people living with a primary immunodeficiency (PID) to
self-report the burden of receiving immunoglobulin treatment. Patients' burden of
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immunoglobulin therapy may vary based on clinical and demo-
graphic characteristics, and patient preferences of treatment
options including modes of administration, frequency, duration
and experience. To develop the IgBoT-35, 395 patients from 10
countries (nine European and Canada) and undergoing either
subcutaneous (67%) or intravenous (32%) administration com-
pleted an online survey. Psychometric tests were undertaken to
identify the questionnaire’s final item pool and domain structure.
This analysis identified eight areas of treatment burden: Time,
Organisation and Planning, Leisure and Social, Interpersonal
Relationships, Employment and Education, Travel,
Consequences of Treatment, and Emotional. A question concern-
ing patient’s perceived overall Ig treatment burden was also
included. Although treatment burden was worse for patients
undergoing intravenous compared to subcutaneous administra-
tion, it was generally lower than anticipated across the different
treatment routes and countries. The IgBoT-35 provides a measure
of Ig treatment burden from the patient’s perspective, for use in
research or clinical practice. It is already translated and usable in
the aforementioned 10 countries. Ig treatment burden appears
generally low, potentially proving reassuring forPID patients
facing subcutaneous and intravenous choices. IgBoT-35 data
may help deliver more individualised and preferred therapies
especially where non-adherence or poor satisfaction with Ig
therapy is observed.
Introduction
Burden of treatment can be defined as the consequences of
receiving treatment (these may be medication, therapies or
other interventions).1,3 It describes the “work of being a
patient” – everything the patient needs to do to treat and
manage their illness, for example, undergoing tests and
investigations, visiting doctors, adhering to treatment regi-
mens and making lifestyle changes.4 It therefore helps us
understand variations in healthcare utilization and adher-
ence in different healthcare settings and clinical contexts.2
Burden of treatment is an important concept because it
may negatively affect adherence to treatment, quality of
life, disease management and healthcare outcomes such as
hospitalisations and survival.5,6
One condition where treatment burden may be high is
in primary immunodeficiency disorders (PIDs). These
occur when the body’s immune response is impaired or
absent which leads to increased susceptibility to infections.
PIDs are caused by hereditary or genetic factors and
represent a group of over 400 disorders with some occur-
ring as often as one per 1,200–2,000 individuals.7
However, the disorders are generally defined as rare with
some only occurring in one per million individuals.
Patients with PIDs need to monitor their health care-
fully and should take precautions to avoid infections,
including maintaining personal hygiene, having a nutri-
tious diet, and not smoking. Modern PID treatments help
patients to live longer and healthier lives than before.
Treatment depends on the type of PID but options include
immunoglobulin (Ig) replacement therapy, granulocyte-
colony stimulating factor, gamma interferon, polyethylene
glycol-modified adenosine deaminase, stem cell transplan-
tation, and gene therapy among others, these last two
being curative, which is not the case of Ig replacement
therapy which is a chronic lifelong supportive treatment.
However, Ig replacement therapy is the main treatment
for most patients with antibody deficiencies and it can be
administered either intravenously (directly into a vein) or
subcutaneously (directly under the skin). Whilst it is gen-
erally accepted that this treatment can dramatically
improve quality of life8,9 it may also be associated with
a substantial treatment burden. Intravenous Ig treatment
(IVIg) is generally administered in hospital and can be
infused every two, three or four weeks lasting approxi-
mately two to four hours per visit. The precise length of
infusion, however, will be dependent on dose and toler-
ance of the individual. Subcutaneous Ig treatment (SCIg)
is typically administered in the home once a week or more
frequently but can be administered in the hospital depend-
ing on patients’ individual needs.
Whilst there are numerous studies which have tried to
measure the quality of life of patients with a PID,8,10 less
attention has focused upon the burden of Ig treatment. The
results of a recent systematic review to explore burden of
Ig treatment in patients with PID revealed that ten different
“health” questionnaires had been used to measure treat-
ment burden.11 Most notable of these were the Life
Quality Index (LQI) or a slightly modified version12,16
which is a condition-specific instrument developed speci-
fically to measure IVIg treatment satisfaction for patients
with a PID, and the Treatment Satisfaction Medication
Questionnaire (TSMQ),17,18 which is a generic instrument
that measures a patient’s satisfaction with treatment.
Several other generic burden of treatment measures exists;
however, none of these have been used in patients with a
PID undergoing Ig treatment. This heterogeneity of differ-
ent measures, subsequently measuring different outcomes
does not enable direct comparison of Ig treatment-related
burden to be easily quantified. A new Ig burden of treat-
ment specific measure may therefore prove a useful mea-
sure for standardising the measurement of Ig treatment
Jones et al Dovepress
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burden across future studies and as newer Ig therapies and
modalities are developed.
The FDA has published guidance for the development
of patient-reported outcome measures, especially those to
be used in clinical trials.19 This describes an iterative
process which has been adhered to as closely as possible
during the development of the IgBoT questionnaire. The
process of developing this new measure has also involved
collaborations between an international team involving
academic, industry and patient partners.
The development of the questionnaire involved four
stages. Stage 1 involved a systematic review of the existing
literature to understand what the burden of Ig therapy may be
in adult patients with primary immunodeficiencies.11 This
review identified the studies that measured the burden of Ig
treatments on adult patients (aged 16 years and older) with
primary immunodeficiencies (PID) and appraised and
synthesised this evidence in relation to the different modes
of Ig administration available and the instruments used. In
Stage 2, semi-structured interviews with 30 patients diag-
nosed with a PID attending the Clinical Immunology and
Allergy Unit (CIAU) in Yorkshire, UK, were undertaken
(Jones et al 2020 under review). Patients receiving IVIg
and SCIg at home or in hospital were included. An inductive
[data-driven] thematic analysis approach was taken to prior-
itise patient accounts/concerns and identify the key concepts
and themes.20
This resulted in a 112-item measure. A further 18 items
were added based upon the findings from the International
literature generated as part of stage 1 around Ig treatment
burden. In stage 3, the face validity of the preliminary
questionnaire was undertaken with an additional 14
patients with PID (who did not take part in the qualitative
interviews) to understand patient’s perceptions of the item
pool and response categories chosen. These were also
recruited via the CIAU but they were not involved in the
qualitative interviews. The 10-item QQ-10 was used to
collect information on the patient’s views on the new
tool.21 The QQ-10 is a measure of face validity, accept-
ability and utility of questionnaire use from the patient’s
perspective and has been used in previous studies. In
addition, a standard proforma consisting of 10 items was
used to ask patients to comment on: 1) How they found the
questionnaire generally, 2) Ease of use, 3) Content, 4)
Language, 5) Relevance and 6) Missing items or areas
not covered. Telephone and face to face meetings were
also held with the large academic, clinical and PPI team to
check the suitability and relevance of the item pool. This
face validity exercise resulted in an initial 129-item
questionnaire.
The aim of this study is to report on stage 4 of the
developmental process. It involved undertaking a large
patient survey using the questionnaire generated in stage
3 to i) reduce the length of the questionnaire, and identify
the salient domains of Ig treatment burden and the scoring
system of the resulting new shorter measure whilst also ii)
using this shorter measure to explore if the burden of
treatment varies according to the route of Ig administra-
tion, by country of residence that took part and by the age
and gender of the patient groups.
Patients and Methods
Design
A 151-item questionnaire was administered in an online,
cross-sectional survey across 10 countries. The 151 items
comprise 1) the 129-item questionnaire generated in stage
3, 2) 18 demographic, PID and treatment-related questions
and 3) four “dummy items” which were also included to
check the scoring patterns of patient’s completing the
questionnaire.
Recruitment and Data Collection
The 10 countries included nine European countries
(United Kingdom, France, Germany, Italy, Poland,
Sweden, Denmark, Norway and the Netherlands), and
Canada. The survey was entered online using Survey
Monkey. Ethical permissions were obtained from the
Independent Ethics Committee (IEC) and the Institutional
Review Board (IRB) according to national and interna-
tional regulations where appropriate. These included:
Germany (Uniklinik Freiburg Ethik komission), Canada
(Schulman IRB), Norway (Regional Ethics Committee
for South-Eastern Norway), UK (South East UK NHS
Ethics Committee), and Italy (La segreteria del Comitato
Etico, Università Federico II). For the Netherlands,
France, Sweden, Poland and Denmark a detailed review
of this study by an independent ethics board was not
mandated by national nor regional guidelines.
Data collection only began in each country after acqui-
sition of a written approval or favourable ethical opinion
was obtained.
Translation and Linguistic Validation
The surveys were translated on the paper version and
linguistically validated with the support of Mapi in
Dovepress Jones et al
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accordance with the guidance of the ISPOR task force for
translation and cultural adaptation.22 The translation pro-
cedure included the following steps: i) Conceptual analysis
and definition, ii) Two forward and one backward transla-
tion, and iii) Cognitive debrief interviews with five PID
patients in each study country. Following migration to
Survey Monkey, all screens were also checked for accu-
racy of translation.
Sample Size
It was anticipated that considering a three to one item to
respondent ratio as recommended, a sample size of 400
would be sufficient to undertake the factor analysis of the
129 items reported below. This was also thought to be
sufficient as generally, a sample size of >300 is considered
adequate.23
Recruitment
In order to achieve an approximate sample size of 400
patients, 450 patients were identified. Patients were invited
to participate in the study by IPOPI and local national
member organisations (NMOs) if they met the following
inclusion criteria: they were 18 years of age and older and
were currently receiving Ig therapy. The treatment had to
be delivered at home or at the hospital and via the intra-
venous or subcutaneous route based on a medical or joint
medical-patient decision. The administration route and
location of where the infusion should be given was already
done before the patient would decide on whether to take
part in the survey.
IPOPI first contacted the study country NMOs in order to
create awareness of the study and determine estimates for the
number of eligible patients in each of the four groups (IVIg
hospital/home or SCIg hospital/home). IPOPI collaborated
with the NMOs to promote the study to doctors, the
International Nursing Group for Immunodeficiencies
(INGID), and national nursing associations. They also pro-
moted the study using a variety of media, including articles,
websites, social media, and/or brochures and requested that
the NMOs communicated details of the study via their web-
sites, newsletters, or social media. All advertising media was
also submitted to the ethics committees for approval.
The NMOs were asked to perform the following: i)
Identify and contact eligible patients to introduce the study
and invite them to take part, ii) send interested and eligible
patients an email containing a link to the online survey in their
local language – this link also contained a unique country-
specific identification number (created by PAREXEL). Only
the NMO knew which identification number corresponded to
which eligible patient (contact details) but did not have access
to the answers provided by the patient to the survey, iii) assign
interested and eligible patients with a unique country-specific
identification number (provided to the NMO by PAREXEL).
If the patient later consented to be contacted for follow-up
questions about their survey responses, the NMOs could then
use the identification number to identify them, and iv) provide
PAREXEL with details of the number of interested and eligi-
ble patients who have been sent a link to the survey and their
unique identification numbers. No identifiable data were col-
lected from patients by PAREXEL, sponsor or the academic
institutions and no details that the NMOs had collected during
this process were shared with PAREXEL, the sponsor or the
academic institutions involved in this research. Also, the
NMO did not have access to the information provided by
the patients to the survey, this information was only accessible
by PAREXEL and linked to the unique country-specific iden-
tification number.
Recruitment was monitored to ensure patients were
equally represented in each of the following groups: IVIg
in hospital, IVIg at home, SCIg in hospital and SCIg at
home. Study participants could withdraw from the study at
any time by not completing the questionnaire or by
requesting withdrawal from their NMO contact. If patients
decided to withdraw, no new data were collected from
them and they were not contacted again. However, the
anonymous data collected before their withdrawal would
still be used in analyses, reports, conference presentations,
and academic journal publications.
Statistical Analyses
The data file was originally received in Excel. This was
converted to SPSS v22. On SurveyMonkey, most of the 133
questionnaire items suitable for the psychometric analysis
(the 129 items + the four dummy items) used a Verbal
Rating Scale ranging between 1 = Never, 2 = Rarely, 3 =
Sometimes, 4 = Often and 5 = Always. A small subset of
items also included an additional “Not Applicable”
response category (coded as 6). For the purposes of this
analyses, the data were recoded from 0 to 5 (5 = Not
Applicable) to support an eventual scoring algorithm of
0–100 (in line with most questionnaires). Only patients
that gave consent to use their survey data were included in
the final analysis.
Exploratory factor analysis (EFA), a method of classi-
cal test construction, was carried out which included the
“not relevant” responses in the procedure. EFA is a
Jones et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Patient Preference and Adherence 2020:141570
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
81
.1
51
.1
67
.2
41
 o
n 
23
-O
ct
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
statistical procedure which enables the underlying dimen-
sions of an instrument to be estimated. It simplifies com-
plicated sets of data into factors using methods such as
principal component analysis (PCA), which is a technique
used to reduce a large number of items on a questionnaire
into a smaller number of dimensions by analysing the
correlations between the individual items. Each factor
that is produced is therefore an indication of the relation-
ships between a set of variables.24 PCA using varimax
rotation (orthogonal rotation), which attempts to identify
interpretable dimensions was used. To test the adequacy of
the sample size for undertaking factor analysis, the Kaiser
Meyer-Olkin and Bartlett’s Test of Sphericity values were
calculated. Values of 0.5 or greater and p<0.0001 are
recommended, respectively.25
To extract the factors, corresponding eigenvalues
greater than 1, scree plots and minimum factor loadings of
0.40 were selected.23,26 The following tests were also used
to examine the domain structure and item pool of the instru-
ment. Cronbach’s alpha reliability coefficient is the measure
which is most frequently used for establishing the internal
consistency reliability of a questionnaire (ie, the extent to
which items within a scale are associated with each other or
the homogeneity of the items) and was calculated in this
study.27 Many different views have been expressed regard-
ing what the minimum reliability coefficient should be for
indicating the internal consistency reliability of a test. For
example, Helmstadter28 postulated that a co-efficient of 0.5
or more was satisfactory whereas Carmines & Zeller29 and
Streiner & Norman30 advocated that the alpha co-efficient
of a scale should ideally exceed 0.8. However, in practice,
an alpha value of 0.7 or more as proposed by Nunnally31 is
most commonly accepted.30
Levels of missing data, floor and ceiling effects (ie, the
percentage of patients who score at the bottom and the top of
the scales), inter-item correlations, missing data and item-
total correlations were also explored which follows good
methodological guidelines for the development of question-
naires. The following thresholds were adopted as reasons for
possible item redundancy: missing data at item level >5%;32
floor and ceiling effects >45% and/or a treatment ceiling of
the “not applicable” answers exceeding 50% and inter-item
correlations >0.3.33 Fifty percent of inter-item correlations
also had to fall within the range 0.30 to 0.70.34
Item-total correlations can also be calculated to check
the internal consistency reliability of a dimension. This is
the extent to which there is a linear relationship between
an item and its scale score which has been corrected for
overlap.35 To correct for overlap the item which is to be
correlated with the scale is omitted from the scale total.
Recommended thresholds can vary between 0.25,32 0.3036
and 0.40 or more.33,37 For the purposes of this study, and
given the large number of items that were included in the
survey, a conservative correlation co-efficient estimate in
between these values of 0.35 was adopted for indicating
satisfactory item-total correlation. The methods employed
were described in the study protocol (v1.4).
Following this analysis, the domain scores were then
calculated. This was computed by summing the scores for
each item in the domain, then dividing by the maximum
score possible for the domain, and then multiplying by 100
to convert the domain score onto a scale of 0–100 (0 = no
Ig treatment burden, 100 = maximum Ig treatment bur-
den). Descriptive statistics (eg, means, medians, standard
deviations, minimum and maximum values, interquartile
ranges and 95% confidence intervals were then calculated
for the sample as a whole and by country of completion.
Finally, t-tests with Bonferroni correction were undertaken
to see if there were any significant differences between the
mean domain scores of those receiving IVIg compared to
SCIg, males compared to females and those aged ±60
years old and an analysis of variance (ANOVA) with
Bonferroni correction was undertaken to explore if domain
scores varied significantly by country. Based on the avail-
ability of domain scores from nine countries, we estimated
a Bonferroni corrected p-value of 0.005 to indicate statis-
tically significant variation in domain score values by
country.
Results
Four hundred and seventy-two patients started the ques-
tionnaire. However, of these 72 patients did not complete
the question giving their consent to use the data, two
patients had a duplicate ID and a further three did not
give a treatment location. Therefore, a total of 395 ques-
tionnaires were eligible for inclusion in the analysis
(83.7%) (Figure 1).
The demographics of the patient sample are shown in
Table 1. With the exception of one patient whose Ig treat-
ment was not reported, most patients were receiving SCIg
treatment (266; 67%) compared to IVIg treatment (128;
32%) and more females (247; 63%) participated compared
to males (147; 37%). The mean age of the sample was
45.9 years (sd=14.6; median=46.0; IQR=35.0–57.0). In
terms of employment, most patients worked full-time
(136; 35%); compared to part-time (63; 16%). The
Dovepress Jones et al
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remainder reported their employment status as disabled
(64; 16%); retired (63; 16%); student (31; 8%); self-
employed (21; 5%); homemaker (6; 2%); unemployed (9;
2%); and missing (2; 1%). Clinical and Ig treatment char-
acteristics are reported in Table 2.
Prior to undertaking the analyses, levels of missing
data, floor and ceiling effects and answers to the not
applicable questions were explored. From this analysis,
71 items were removed because they exceeded the mini-
mum thresholds. However, although four items exceeded
the 45% cut-off for floor and ceiling effects ie, “labour
intensive”, “other illness worries”, “an unexpected reac-
tion” and “time worries” because these were considered
conceptually important based upon team meetings and the
themes actively generated from the qualitative interviews
they were kept in at this stage.
Following this only one dummy question remained
which was also removed (“felt negative about my treat-
ment”) because after checking the pattern of scoring with
its twin question, the pattern of scoring was in the appro-
priate direction. The overall Ig burden item was also
excluded. Given that most of the positively worded items
had been removed, it was decided to also remove the
remaining seven positively phrased items to avoid the
complexities of possible recoding and interpreting nega-
tive correlations for potential users of the new measure in
the future. Therefore, a total of 80 items were excluded
leaving 53 items that were used in the first round of factor
analysis. Following discussions within the clinical and
statistical team, for the purposes of the factor analysis,
those patients that answered “not applicable” to any item
were recoded to 0 meaning “never”, rather than designated
missing from the dataset. This was because the wording of
the questions was such that a response of burden being
“not applicable” was semantically comparable with an
item “never” being burdensome.
An initial factor analysis was undertaken on the 395-
patient sample. In the first instance, multicollinearity was
explored to check which items did not appear to be corre-
lated with any other variables or correlated too highly.
After reviewing the correlation matrix, it was decided to
remove a further two items (swelling and tight skin)
because they appeared to be negatively correlated with
many of the items. The analysis was then run again.
Having removed these items, the Kaiser-Meyer Olkin
value was 0.927 and the Bartlett’s test of Sphericity was
significant (p<0.0001), thus indicating that the sample size
was adequate.
Figure 1 Flowchart to show patient completion of the online survey.
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From the data, 11 factors were extracted accounting for
63% of the variability in the data. However, only the first
nine appeared meaningful accounting for 58% of the varia-
bility. These nine factors appeared to measure 1) time and
organisational and planning burden (9 items), 2) leisure
and social activities burden (6 items), 4) emotional burden
(5 items), 5) travel burden (5 items), 7) interpersonal
relationships and activities (6 items), 8) employment and
education burden (3 items), and factors 3, 6 and 9 related
to psychological consequences and physical consequences
(eg, side effects) of treatment (11 items). Two items failed
to load significantly within these nine factors (insurance
and others understanding what going through) and so were
omitted from the analysis.
It was decided that the first factor would be best sepa-
rated into two domains. In the emotional burden domain,
conceptually one item (“others worry”) was felt not to fit
and so was removed from the analysis. Some additional
potential items were also removed at this stage based upon
conceptual reasoning (ie, considering the information gen-
erated from the systematic review and qualitative inter-
views). This resulted in a 34-item questionnaire, with eight
Table 1 Patient Characteristics by Ig Treatment Group
Total
ie Number of Eligible Questionnaires
Intravenous
Ig
Subcutaneous
Ig
N (The treatment for one patient was not reported). 395 (100%) 128 (32%) 266 67%)
Country
Canada 24 (7.1%) 9 (8.7%) 15 (6.4%)
Denmark 36 (10.7%) 2 (1.9%) 34 (14.6%)
France 23 (6.8%) 10 (9.6%) 13 (5.6%)
Germany 59 (17.5%) 5 (4.8%) 54 (23.2%)
Italy 28 (8.3%) 5 (4.8%) 23 (9.9%)
Netherlands 58 (17.2%) 46 (44.2%) 12 (5.2%)
Norway 49 (14.5%) 17 (16.3%) 31 (13.3%)
Poland 16 (4.7%) 4 (3.8%) 12 (5.2%)
Sweden 45 (13.3%) 6 (5.8%) 39 (16.7%)
UK 57 (14.4%) 24 (18.8%) 33 (12.4%)
Age (years)
Mean (standard deviation) 45.9 (14.6) 45.3 (14.8) 46.1 (14.5)
Median (interquartile range) 46.0 (35.0–57.0) 46.0 (33.8–57.2) 46.0 (36.0–56.0)
Range 18.0–83.0 18.0–83.0 19.0–79.0
Missing 0 (0%) 0 (0%) 0 (0%)
Sex
Male 147 (37.3%) 57 (44.5%) 90 (34.0%)
Female 247 (62.7%) 71 (55.5%) 175 (66.0%)
Missing 1 (0.3%) 0 (0.0%) 1 (0.4%)
Employment
Employed full-time 136 (34.6%) 41 (32.0%) 94 (35.6%)
Employed part-time 63 (16.0%) 21 (16.4%) 42 (15.9%)
Self-employed 21 (5.3%) 8 (6.2%) 13 (4.9%)
Homemaker 6 (1.5%) 4 (3.1%) 2 (0.8%)
Student 31 (7.9%) 9 (7.0%) 22 (8.3%)
Retired 63 (16.0%) 15 (11.7%) 48 (18.2%)
Disabled/unable to work 64 (16.3%) 28 (21.9%) 36 (13.6%)
Unemployed but looking for work 7 (1.8%) 2 (1.6%) 5 (1.9%)
Unemployed and not looking for work 2 (0.5%) 0 (0.0%) 2 (0.8%)
Missing 2 (0.5%) 0 (0.0%) 2 (0.8%)
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domains plus an additional item relating to “global Ig
treatment burden” which falls outside of the scored
domains (Table 3).
PCAwas repeated on these 34 items and sevenmeaningful
factors were identified which accounted for 61.7% of the
variance. Therewas no change to the planned domain structure
as described above (Table 3). All the inter-item correlations
were positive, suggesting that the items aremeasuring the same
underlying constructs, and 97% of the inter-item correlations
fell within the range 0.30 to 0.70 (Nunnally, 1994). In addition,
Table 2 Clinical Characteristics by Treatment Route
Total,
ie, Number of Eligible
Questionnaires
Intravenous
Ig
Subcutaneous
Ig
N (The treatment for one patient was not reported). 395 (100%) 128 (32%) 266 (67%)
Type of device for SCIG treatment†
†Two SCIG users selected the IVIG option
and 28 IVIG users specified SCIG device
Not applicable (IVIg treatment only) 128 (32.0%) 128 (32.0%) NA
Manual syringe push (by hand) 21 (5.4%) 0 (0.0%) 21 (8.0%)
Mechanical syringe pump (syringe pump without a battery) 29 (7.5%) 0 (0.0%) 29 (11.1%)
Electromechanical syringe pump (syringe pump which uses a battery or needs to be
plugged in)
209 (54.0%) 12 (9.6%) 196 (75.1%)
Electromechanical pump which infuses from a bag/cartridge/reservoir (pumps from
something other than a syringe)
27 (7.0%) 15 (12.0%) 12 (4.6%)
Do not know/unsure 2 (0.5%) 1 (0.8%) 1 (0.4%)
Missing 8 (2.0%) 3 (2.3%) 5 (1.9%)
Duration of Ig treatment (years)
Mean (standard deviation) 7.3 (4.1) 9.1 (3.8) 6.4 (4.0)
Median (interquartile range) 7.0 (3.0–12.0) 12.0 (6.0–12.0) 6.0 (3.0–11.0)
Range 1.0–12.0 1.0–12.0 1.0–12.0
Missing 5 (1.3%) 1 (0.8%) 4 (1.5%)
Number of hospitalizations for PID-related reasons in the previous 12 months
Mean (standard deviation) 1.4 (1.1) 1.5 (1.4) 1.3 (0.9)
Median (interquartile range) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
Range 1.0–12.0 1.0–12.0 1.0–7.0
Missing 4 (1.0%) 0 (0%) 4 (1.5%)
Number of infections requiring a visit to a healthcare professional in the previous 12 months
Mean (standard deviation) 4.5 (2.9) 4.4 (3.0) 4.5 (2.8)
Median (interquartile range) 4.0 (2.0–6.0) 4.0 (2.0–6.0) 4.0 (3.0–6.0)
Range 1.0–12.0 1.0–12.0 1.0–12.0
Missing 6 (1.5%) 1 (0.8%) 5 (1.9%)
Number of hospitalizations for other reasons (other than infections but PID-linked) in the previous 12 months
Mean (standard deviation) 1.4 (1.1) 1.4 (1.1) 1.5 (1.2)
Median (interquartile range) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
Range 1.0–12.0 1.0–9.0 1.0–12.0
Missing 6 (1.5%) 2 (1.6%) 4 (1.5%)
Regular use of oral/inhaled antibiotics
Yes 115 (29.5%) 52 (41.3%) 63 (24.0%)
No 270 (69.2%) 74 (58.7%) 195 (74.1%)
Do not know/unsure 5 (1.3%) 0 (0.0%) 5 (1.9%)
Missing 5 (1.3%) 2 (1.6%) 3 (1.1%)
Jones et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Patient Preference and Adherence 2020:141574
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
81
.1
51
.1
67
.2
41
 o
n 
23
-O
ct
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Table 3 Domain Structure, Item Pool and Reliability of the Domains Generated from the Exploratory Factor Analysis
Because of My Current Ig Treatment, I Have
……………….
Items Alpha Average Inter-Item
Correlations
Range of Inter-Item
Correlations
Item-Total Correlations
(Corrected for Overlap)
F1. Time Burden (n = 379) 4 0.82 0.54 0.41–0.60
Felt that my treatment takes up too much time 0.72
Felt that my treatment is too frequent 0.57
Found that I worry about the time needed to have my
treatment
0.67
Found it challenging to find the time for my treatment 0.63
F2. Organisation and Planning Burden (n = 373) 5 0.83 0.48 0.31–0.69
Felt that having my treatment takes too much effort. 0.71
Found keeping to a strict routine to manage my
treatment hard work
0.67
Found that planning ahead to have my treatment takes
effort
0.68
Found having my treatment inconvenient 0.69
Found it labour intensive to set up the equipment
needed for my Ig treatment (eg pumps)
0.39
F3. Leisure and Social Burden (n=373) 5 0.81 0.47 0.39–0.60
Found that having my treatment disrupts my holidays 0.63
Found that my treatment stops me from travelling 0.57
Found that I miss out on doing other things I would
prefer to do.
0.64
Found that my life revolves around taking the treatment 0.56
Found that my treatment interferes with my daily
activities
0.63
F4. Emotional Burden (n= 376) 3 0.82 0.61 0.56–0.70
Felt annoyed at having my Ig treatment 0.71
I feel unhappy to have my Ig treatment 0.70
I struggle to come to terms with having this treatment
forever
0.62
F5. Travel Burden (n = 379) 5 0.77 0.40 0.32–0.66
Found travelling for my treatment inconvenient 0.53
Found that finding a parking space to have my treatment
causes me problems
0.46
I have to travel a long distance to have my Ig treatment 0.65
Had to rely on others to travel for my treatment 0.50
Found the travel costs associated with my treatment
expensive
0.60
F6. Interpersonal Relationship Burden (n=375) 3 0.81 0.58 0.49–0.72
Found that it disrupts my family’s routine 0.73
Found that it interferes with my ability to look after my
family
0.70
Found that arranging it around the timetables of others
is awkward
0.55
F7. Employment and Education Burden (n = 383) 3 0.81 0.59 0.57–0.61
Had to take time off education/school/work 0.66
Found that taking time off to have my treatment has
made me worry
0.68
Found that I have had to adjust my working hours 0.65
F8. Consequences of Treatment Burden (n=376) 6 0.71 0.28 0.13–0.48
Found it painful when the needle is inserted 0.44
Found that I get bruising at the site of the treatment 0.36
(Continued)
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all the alpha values exceeded the minimum threshold of 0.70
suggesting acceptable levels for each of the domains (Table 3).
The purpose of the proposed IgBoT-35 instrument is to
indicate the extent of self-reported Ig treatment burden on
each item and domain measured. The raw scores for each
IgBoT-35 item are reported in Table 4. Each scale was
then standardised on a scale of 0–100. Scale scores for the
sample overall are shown in Table 5. Descriptive statistics
of the IgBoT-35 mean scores by country have been pro-
vided in graphical (Figure S1–9) and tabular form
(Table S1).
For the overall sample overall, treatment burden
appeared to be generally low across each item (Table 4)
and domain (Table 5). Whilst the time burden was gener-
ally low across all countries, it was highest in France
(mean: 45.4) and lowest in Sweden (mean: 21.5).
Organisation and planning burden was low across all
countries. It was highest in France (mean: 33.8) and lowest
in Germany (mean: 16.9). Leisure/social burden was low
across all countries. It was highest in France (mean: 51.4)
and lowest in Norway (mean: 23.0). Interpersonal relation-
ship burden was low across all countries. It was highest in
France (mean: 40.2) and lowest in Italy (mean: 14.2).
Employment and education burden was low across all
countries. It was highest in France (mean: 39.5) and lowest
in Sweden (mean: 9.2). Travel burden was low across all
countries. It was highest in Poland (mean: 28.8) and low-
est in Denmark (mean: 8.9). Consequences of treatment
burden was low across all countries. It was highest in
France (mean: 35.6) and lowest in Germany (mean:
23.3). Finally, the single item “Global Ig treatment bur-
den” was low across all countries. It was highest in France
(mean: 54.5) and lowest in Italy (mean: 24.1) (Figure S1–9
and Table S1). One-way ANOVA to test for differences in
domain values between countries revealed that none were
Bonferroni-significant (Tables S2–10).
In relation to Ig treatment route, burden was low across
both IVIg and SCIg (Table 6). Despite this, with the exception
of the emotional well-being domain, treatment burden was
observed to be higher for those receiving IVIg compared to
SCIg therapy, particularly in the three areas of leisure/social
activities, interpersonal relationship, employment and educa-
tion, and travel (P<0.005). Generally, mean IgBoT-35 domain
scores were higher for women than men with the exception of
the leisure/social domain and the employment and education
domain, and significantly higher for women in the conse-
quences of treatment domain (P<0.005). However, overall
these differences were very small (eg, less than 3 points on
some scales) (Table 7). In terms of age, the sample was
categorised into those younger and older than 60 (Table 8).
For all domains, mean IgBoTscores were higher in those aged
younger than 60 years of age compared to those aged older
than this and significantly worse in the time, interpersonal
relationships, employment and education and emotional bur-
den domains (P<0.005).Whilst overall themean burden scores
were generally lower than anticipated, they were worse for
those on hospital compared to home treatment and signifi-
cantly worse on the leisure and social, education and employ-
ment and travel domains (P<0.005) (Table 9).
Discussion
The aim of this study was to develop the first Ig patient-
generated burden of treatment questionnaire for patients
living with a PID and to start to quantify the perceived
impact of Ig treatment from PID patients receiving this
therapy across Europe and Canada.
The psychometric analysis resulted in a questionnaire
comprising eight domains and 34 items which covered
various aspects of Ig related treatment burden: time (4
items), organisation and planning (5 items), leisure and
social (5 items), interpersonal relationships (3 items),
employment and education (3 items), travel (5 items),
consequences of treatment (6 items), and emotional (3
Table 3 (Continued).
Because of My Current Ig Treatment, I Have
……………….
Items Alpha Average Inter-Item
Correlations
Range of Inter-Item
Correlations
Item-Total Correlations
(Corrected for Overlap)
Had an unexpected reaction to my Ig treatment 0.39
Found my treatment uncomfortable 0.56
Felt worried about catching another illness from my
treatment
0.37
Felt worried about having an unexpected reaction to my
treatment
0.51
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Table 4 Raw Data of the IgBoT-35 Items
Because of My Current Ig Treatment, I Have ………………. Never Rarely Sometimes Often Always Not
Relevant
Missing
N (%) N (%) N (%) N (%) N (%) N (%) N (%)
F1. Time Burden (n = 379)
Felt that my treatment takes up too much time 124 (31.2) 111 (27.9) 90 (22.6) 31 (7.8) 25 (6.3) 0 (0) 17 (4.3)
Felt that my treatment is too frequent 170 (42.7) 75 (18.8) 80 (20.1) 36 (9.0) 20 (5.0) 0 (0) 17 (4.3)
Found that I worry about the time needed to have my treatment 187 (47.0) 91 (22.9) 73 (18.3) 23 (5.8) 6 (1.5) 0 (0) 18 (4.5)
Found it challenging to find the time for my treatment 132 (33.2) 115 (28.9) 98 (24.6) 30 (7.5) 8 (2.0) 0 (0) 15 (3.8)
F2. Organisation and Planning Burden (n = 373)
Felt that having my treatment takes too much effort. 177 (44.5) 118 (29.6) 56 (14.1) 20 (5.0) 7 (1.8) 0 (0) 20 (5.0)
Found keeping to a strict routine to manage my treatment hard work 179 (45.0) 91 (22.9) 82 (20.6) 18 (4.5) 9 (2.3) 0 (0) 19 (4.8)
Found that planning ahead to have my treatment takes effort 138 (34.7) 119 (29.9) 87 (21.9) 23 (5.8) 12 (3.0) 0 (0) 19 (4.8)
Found having my treatment inconvenient 134 (33.7) 124 (31.2) 83 (20.9) 24 (6.0) 13 (3.3) 0 (0) 20 (5.0)
Found it labour intensive to set up the equipment needed for my Ig
treatment (eg pumps)
196 (49.2) 58 (14.6) 34 (8.5) 4 (1.0) 5 (1.3) 86 (21.6) 15 (3.8)
F3. Leisure and Social Burden (n=373)
Found that having my treatment disrupts my holidays 118 (29.6) 119 (29.9) 87 (21.9) 23 (5.8) 12 (3.0) 0 (0) 19 (4.8)
Found that my treatment stops me from travelling 166 (41.7) 89 (22.4) 81 (20.4) 32 (8.0) 10 (2.5) 0 (0) 20 (5.0)
Found that I miss out on doing other things I would prefer to do. 109 (27.4) 125 (31.4) 99 (24.9) 40 (10.1) 10 (2.5) 0 (0) 15 (3.8)
Found that my life revolves around taking the treatment 141 (35.4) 108 (27.1) 78 (19.6) 36 (9.0) 16 (4.0) 0 (0) 19 (4.8)
Found that my treatment interferes with my daily activities 101 (25.6) 131 (33.2) 95 (24.1) 37 (9.4) 13 (3.3) 0 (0) 18 (4.6)
F4. Emotional Burden (n= 376)
Felt annoyed at having my Ig treatment 154 (39.0) 104 (26.3) 71 (18.0) 33 (8.4) 14 (3.5) 0 (0) 22 (5.5)
I feel unhappy to have my Ig treatment 146 (37.0) 109 (27.6) 80 (20.3) 31 (7.8) 11 (2.8) 0 (0) 21 (5.3)
I struggle to come to terms with having this treatment forever 132 (33.4) 79 (20.0) 79 (20.0) 51 (12.9) 35 (8.9) 0 (0) 22 (5.5)
F5. Travel Burden (n = 379)
Found travelling for my treatment inconvenient 117 (29.4) 61 (15.3) 63 (15.8) 17 (4.3 9 (2.3) 121 (30.4) 10 (2.5)
Found that finding a parking space to have my treatment causes me
problems
144 (36.2) 28 (7.0) 17 (4.3) 13 (3.3) 11 (2.8) 175 (44.0) 10 (2.5)
I have to travel a long distance to have my Ig treatment 166 (41.7) 21 (5.3) 25 (6.3) 7 (1.8) 32 (8.0) 136 (34.2) 11 (2.8)
Had to rely on others to travel for my treatment 163 (41) 17 (4.3) 20 (5.0) 8 (2.0) 22 (5.5) 157 (39.4) 11 (2.8)
Found the travel costs associated with my treatment expensive 156 (39.2) 29 (7.3) 17 (4.3) 9 (2.3) 20 (5.0) 155 (38.9) 12 (3.0)
F6. Interpersonal Relationship Burden (n=375)
Found that it disrupts my family’s routine 114 (28.6) 106 (26.6) 95 (23.9) 29 (7.3) 11 (2.8) 28 (7.0) 15 (3.8)
Found that it interferes with my ability to look after my family 151 (37.9) 80 (20.1) 66 (16.6) 26 (6.5) 7 (1.8) 52 (13.1) 15 (3.8)
Found that arranging it around the timetables of others is awkward 161 (40.5) 107 (26.9) 85 (21.4) 19 (4.8) 6 (1.5) 0 (0) 20 (5.3)
F7. Employment and Education Burden (n = 383)
Had to take time off education/school/work 106 (26.6) 59 (14.8) 34 (8.5) 22 (5.5) 30 (7.5) 133 (33.4) 14 (3.5)
Found that taking time off to have my treatment has made me worry 115 (28.9) 39 (9.8) 30 (7.5) 21 (5.3) 21 (5.3) 158 (39.7) 14 (3.5)
Found that I have had to adjust my working hours 138 (34.7) 29 (7.3) 37 (9.3) 18 (4.5) 31 (7.8) 130 (32.7) 15 (3.8)
F8. Consequences of Treatment Burden (n=376)
Found it painful when the needle is inserted 34 (8.6) 115 (29.1) 151 (38.2) 50 (12.7) 26 (6.6) 0 (0) 22 (5.5)
Found that I get bruising at the site of the treatment 85 (21.4) 125 (31.4) 113 (28.4) 41 (10.3) 14 (3.5) 0 (0) 20 (5.0)
Had an unexpected reaction to my Ig treatment 205 (51.9) 101 (25.6) 53 (13.4) 16 (4.1) 3 (0.8) 0 (0) 17 (4.3)
Found my treatment uncomfortable 104 (26.1) 139 (34.9) 88 (22.1) 33 (8.3) 14 (3.5) 0 (0) 20 (5.0)
Felt worried about catching another illness from my treatment 200 (50.3) 86 (21.6) 68 (17.1) 19 (4.8) 5 (1.3) 0 (0) 20 (5.0)
Felt worried about having an unexpected reaction to my treatment 171 (43.0) 112 (28.1) 65 (16.3) 23 (5.8) 7 (1.8) 0 (0) 20 (5.0)
Note: *Represents that whilst ‘some values slightly exceeded the floor threshold of 45% and missing value of 5%+, they were not removed because they were considered
conceptually important based upon team meetings and the themes actively generated from the qualitative interviews.
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items). Lastly, an additional Ig treatment burden global
question was included at the end of the measure (n=35
items in total). The internal reliability of the questionnaire
was high with all the scales exceeding the accepted alpha
value of 0.70 for comparisons at a group level. The ques-
tionnaire also demonstrated acceptable levels of inter-item
correlations and item-total correlations.
The dimensions produced on the questionnaire reflect
the many areas of treatment burden that patients under-
going Ig therapy may experience. The finding that treat-
ment burden was generally low across the different
treatment routes and countries is supported by recent evi-
dence generated from a systematic review of the interna-
tional literature on Ig treatment burden for patients with a
PID10 and a smaller, in-depth qualitative study to explore
the concerns of 30 patients in the UK support this finding
too (Jones et al, under peer review).
Whilst the treatment burden was lower than antici-
pated, the analysis by route of administration revealed
higher scores (higher burden) in patients receiving intra-
venous therapy in all domains (including leisure and
social, interpersonal, travel and education), the only excep-
tion was on the emotional burden domain. Similar findings
have been observed in other published studies.11 However,
further research is needed to determine if these differences
in scores as measured on the new questionnaire are repli-
cated and to explore what other factors may be driving
these differences.
The finding that those aged under 60 reported more Ig
treatment-related burden is perhaps not surprising, given
that this cohort of patients are more likely to be in employ-
ment and have younger families, school and education
commitments to organise their Ig therapy around.
However, further work to explore age-related Ig treatment
impacts is needed to understand, for instance, the impact
of receiving Ig as a lifelong treatment. Overall, women
reported more Ig burden across all the domains and on the
global single item compared to their male counterparts
with the exception of the leisure and social domain and
employment and education domains. However, given that
the differences across the domains overall were very small,
more work is needed to explore these possible gender
differences further.
In terms of psychometric robustness, the English ver-
sion of the instrument was generated from qualitative work
with UK patients, a systematic review and expert feedback
and internal peer review with members of the international
study team thus supporting the content validity of the
Table 5 Mean Domain Scores for the IgBoT-35 for the Total Patient Sample
Domain
0 = No Ig
Treatment Burden,
100 = MAXIMUM
Ig TREATMENT
Burden
Number of
Non-Missing
Scores
Domain Score Number (%) with
Not Applicable
Responses
Number (%)
of Missing
Scores
Mean
(Standard
Deviation)
95% CI Median Interquartile
Range
Min–Max
1. Time Burden 379 27.4 (22.7) 25.2–29.7 25 12.5–43.8 0.0–100.0 0 (0%) 16 (4%)
2. Organization and
Planning Burden
373 21.8 (19.3) 19.8–23.7 15 5.0–35.0 0.0–100.0 86 (23%) 22 (6%)
3. Leisure/Social
Burden
373 30.1 (21.1) 28.0–32.2 25 15.0–45.0 0.0–90.0 0 (0%) 22 (6%)
4. Interpersonal
Relationship Burden
375 24.2 (22.2) 21.9–26.4 16.7 8.3–41.7 0.0–100.0 53 (14%) 20 (5%)
5. Employment and
Education Burden
383 18.3 (26.5) 15.6–21.0 0 0.0–33.3 0.0–100.0 234 (61%) 12 (3%)
6. Travel Burden 380 12.7 (19.4) 10.8–14.6 0 0.0–20.0 0.0–100.0 209 (55%) 15 (4%)
7. Consequences of
Treatment Burden
376 28.4 (16.1) 26.8–30.1 25 16.7–37.5 0.0–79.2 0 (0%) 19 (5%)
8. Emotional Burden 376 29.6 (25.5) 27.1–32.2 25 8.3–50.0 0.0–100.0 0 (0%) 19 (5%)
Global Ig Treatment
Burden
374 38.2 (25.5) 35.7–40.8 25 25.0–50.0 0.0–100.0 0 (0%) 21 (5%)
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measure. Face validity was also demonstrated in a smaller
survey with UK patients reported elsewhere. Whilst this
survey has substantially reduced the questionnaire, identi-
fied the domain structure, scoring algorithms and aspects
of reliability, based upon the FDA guidance for the devel-
opment of PROMS, there are still a number of other
psychometric analyses to undertake.19 Therefore, a second
online survey with patients undergoing Ig therapy in the
US is currently being undertaken using this shorter mea-
sure. This study will be used to test the current model of
the IgBoT-35 and reduce it further if appropriate. The data
will also be used to evaluate the other psychometric
properties of the questionnaire which are currently un-
determined, such as aspects of construct and criterion
validity using “a priori” hypotheses developed by the
team. A comparison of the mean treatment scores are
also planned to see if the levels of Ig treatment burden
observed from this first survey are similar to those
reported by patients in the US.
Limitations
There were some limitations to the study. Due to the
need to translate the questionnaire into nine different
languages, the format of some of the items changed
Table 6 Domain Summary Statistics by Administration Route (IVIG/SCIG)
Domain/Administration Route
0 = No Ig Treatment Burden,
100 = Maximum Ig Treatment
Burden
Number
of Non-
Missing
Scores
Domain Score Number
(%) with
Not
Applicable
Responses
Number
(%) of
Missing
Scores
P value
Bonferroni
Significant
(p≤0.005)=
***
Mean
(Standard
Deviation)
95% CI Median Interquartile
Range
Min–Max
1. Time Burden 379 27.4 (22.7) 25.2–29.7 25 12.5–43.8 0.0–100.0 0 (0%) 16 (4%) P>0.005
● IVIg 123 30.1 (24.9) 25.7–34.5 25 12.5–46.9 0.0–100.0 0 (0%) 5 (4%)
● SCIg 255 26.0 (21.4) 23.4–28.6 25 6.2–37.5 0.0–100.0 0 (0%) 11 (4%)
2. Organization and Planning Burden 373 21.8 (19.3) 19.8–23.7 15 5.0–35.0 0.0–100.0 86 (23%) 22 (6%) P>0.005
● IVIg 122 22.1 (18.2) 18.9–25.3 20 5.0–35.0 0.0–85.0 71 (58%) 6 (5%)
● SCIg 250 21.5 (19.8) 19.1–24.0 15 5.0–35.0 0.0–100.0 14 (6%) 16 (6%)
3. Leisure/Social Burden 373 30.1 (21.1) 28.0–32.2 25 15.0–45.0 0.0–90.0 0 (0%) 22 (6%) P<0.005***
● IVIg 122 37.5 (23.9) 33.3–41.8 35 20.0–55.0 0.0–90.0 0 (0%) 6 (5%)
● SCIg 250 26.4 (18.5) 24.1–28.7 25 10.0–40.0 0.0–80.0 0 (0%) 16 (6%)
4. Interpersonal Relationship Burden 375 24.2 (22.2) 21.9–26.4 16.7 8.3–41.7 0.0–100.0 53 (14%) 20 (5%) P<0.005***
● IVIg 123 30.6 (24.8) 26.2–35.0 25 8.3–41.7 0.0–100.0 28 (23%) 5 (4%)
● SCIg 251 21.0 (20.1) 18.5–23.5 16.7 0.0–33.3 0.0–83.3 24 (10%) 15 (6%)
5. Employment and Education
Burden
383 19.7 (23.8) 17.4–22.1 12.5 0.0–31.2 0.0–100.0 234 (61%) 12 (3%) P<0.005***
● IVIg 125 30.3 (32.1) 24.7–36.0 25 0.0–58.3 0.0–100.0 71 (57%) 3 (2%)
● SCIg 257 12.2 (20.9) 9.7–14.8 0 0.0–16.7 0.0–100 162 (63%) 9 (3%)
6. Travel Burden 380 12.7 (19.4) 10.8–14.6 0 0.0–20.0 0.0–100.0 209 (55%) 15 (4%) P<0.005***
● IVIg 124 20.7 (23.8) 16.5–24.9 15 0.0–35.0 0.0–100.0 60 (48%) 4 (3%)
● SCIg 255 8.7 (15.3) 6.8–10.6 0 0.0–10.0 0.0–85.0 148 (58%) 11 (4%)
7. Consequences of Treatment
Burden
376 28.4 (16.1) 26.8–30.1 25 16.7–37.5 0.0–79.2 0 (0%) 19 (5%) P>0.005
● IVIg 123 30.4 (16.5) 27.4–33.3 29.2 18.8–41.7 0.0–79.2 0 (0%) 5 (4%)
● SCIg 252 27.4 (15.8) 25.5–29.4 25 16.7–37.5 0.0–79.2 0 (0%) 14 (5%)
8. Emotional Burden 376 29.6 (25.5) 27.1–32.2 25 8.3–50.0 0.0–100.0 0 (0%) 19 (5%) P>0.005
● IVIg 123 26.8 (22.4) 22.9–30.8 25 8.3–41.7 0.0–100.0 0 (0%) 5 (4%)
● SCIg 252 30.9 (26.8) 27.6–34.2 25 8.3–50.0 0.0–100.0 0 (0%) 14 (5%)
Global Ig Treatment Burden 374 38.2 (25.5) 35.7–40.8 25 25.0–50.0 0.0–100.0 0 (0%) 21 (5%) P>0.005
● IVIg 122 41.0 (26.5) 36.3–45.7 50 25.0–50.0 0.0–100.0 0 (0%) 6 (5%)
● SCIg 251 36.9 (24.9) 33.8–39.9 25 25.0–50.0 0.0–100.0 0 (0%) 15 (6%)
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based upon the outcome of the cognitive interviewing.
The most important change was that on the initial paper
version of the instrument, it was only planned to have
the header question “because of my current Ig treatment,
I have ….” at the top of each page. However, due to the
nature of SurveyMonkey, this was changed so that this
header was used at the start of each item. This made
some of the items long and more challenging to read,
for example, “because of my current Ig treatment, I
have found that my Ig treatment takes up too much
time.”
Given the extent of item reduction that was needed with
this first survey, item reduction was undertaken cautiously
and there is potentially scope for some more item redun-
dancy. There may also be problems with the “consequence of
treatment” domain as some of these items cross-loaded but
this will be explored further in the new data set before
confirming the final domain structure. It may be that this
domain will be shortened or removed depending on the
results from the next set of analyses.
The whole questionnaire (including the demographic and
IgBoT questions) that was entered onto SurveyMonkey was
Table 7 Domain Summary Statistics by Gender (Female/Male)
Domain/Gender
0 = No Ig Treatment
Burden,
100 = Maximum Ig
Treatment Burden
Number
of Non-
Missing
Scores
Domain Score Number
(%) with
Not
Applicable
Responses
Number
(%) of
Missing
Scores
P value
Bonferroni
Significant
(p≤0.005)=
***
Mean
(Standard
Deviation)
95% CI Median Interquartile
range
Range
1. Time Burden 379 27.4 (22.7) 25.2–29.7 25 12.5–43.8 0.0–100.0 0 (0%) 16 (4%) P>0.005
● Female 237 28.6 (23.4) 25.7–31.6 25 12.5–43.8 0.0–100.0 0 (0%) 10 (4%)
● Male 141 25.6 (21.3) 22.1–29.1 18.8 12.5–37.5 0.0–87.5 0 (0%) 6 (4%)
2. Organization and
Planning Burden
373 21.8 (19.3) 19.8–23.7 15 5.0–35.0 0.0–100.0 86 (23%) 22 (6%) P>0.005
● Female 232 22.4 (20.3) 19.8–25.0 15 5.0–35.0 0.0–100.0 58 (25%) 15 (6%)
● Male 140 20.9 (17.4) 18.0–23.7 15 8.8–30.0 0.0–85.0 28 (20%) 7 (5%)
3. Leisure/Social Burden 373 30.1 (21.1) 28.0–32.2 25 15.0–45.0 0.0–90.0 0 (0%) 22 (6%) P>0.005
● Female 232 29.7 (21.1) 27.0–32.4 25 15.0–45.0 0.0–90.0 0 (0%) 15 (6%)
● Male 140 30.8 (21.2) 27.3–34.3 25 15.0–45.0 0.0–90.0 0 (0%) 7 (5%)
4. Interpersonal
Relationship Burden
375 24.2 (22.2) 21.9–26.4 16.7 8.3–41.7 0.0–100.0 53 (14%) 20 (5%) P>0.005
● Female 234 24.9 (22.7) 21.9–27.8 20.8 8.3–41.7 0.0–100.0 37 (16%) 13 (5%)
● Male 140 23.2 (21.2) 19.6–26.7 16.7 8.3–35.4 0.0–75.0 16 (11%) 7 (5%)
5. Employment and
Education Burden
383 18.3 (26.5) 15.6–21.0 0 0.0–33.3 0.0–100.0 189 (49%) 12 (3%) P>0.005
● Female 239 17.3 (27.2) 13.9–20.7 0 0.0–33.3 0.0–100.0 137 (57%) 8 (3%)
● Male 143 20.0 (25.5) 15.8–24.2 8.3 0.0–33.3 0.0–100.0 52 (36%) 4 (3%)
6. Travel Burden 380 12.7 (19.4) 10.8–14.6 0 0.0–20.0 0.0–100.0 209 (55%) 15 (4%) P>0.005
● Female 237 13.4 (20.1) 10.8–15.9 5 0.0–20.0 0.0–100.0 140 (59%) 10 (4%)
● Male 142 11.7 (18.2) 8.7–14.6 0 0.0–18.8 0.0–95.0 69 (49%) 5 (3%)
7. Consequences of
Treatment Burden
376 28.4 (16.1) 26.8–30.1 25 16.7–37.5 0.0–79.2 0 (0%) 19 (5%) P<0.005***
● Female 235 31.0 (16.9) 28.8–33.1 29.2 16.7–41.7 0.0–79.2 0 (0%) 12 (5%)
● Male 140 24.2 (13.7) 22.0–26.5 20.8 12.5–33.3 0.0–58.3 0 (0%) 7 (5%)
8. Emotional Burden 376 29.6 (25.5) 27.1–32.2 25 8.3–50.0 0.0–100.0 0 (0%) 19 (5%) P>0.005
● Female 235 31.7 (26.2) 28.3–35.0 25 8.3–50.0 0.0–100.0 0 (0%) 12 (5%)
● Male 140 26.2 (24.0) 22.3–30.2 25 8.3–41.7 0.0–100.0 0 (0%) 7 (5%)
Global Ig Treatment
Burden
374 38.2 (25.5) 35.7–40.8 25 25.0–50.0 0.0–100.0 0 (0%) 21 (5%) P>0.005
● Female 233 40.3 (26.2) 37.0–43.7 50 25.0–50.0 0.0–100.0 0 (0%) 14 (6%)
● Male 140 35.0 (23.8) 31.1–38.9 25 25.0–50.0 0.0–100.0 0 (0%) 7 (5%)
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long and included 151 items. There was evidence of ques-
tionnaire fatigue because missing data was more evident
towards the end of the questionnaire but unfortunately, we
did not record completion times. Ideally, more time and
opportunity to validate the different language versions of
the questionnaire prior to being migrated from the paper to
electronic version would have been beneficial (beyond the
five patients per country used by MAPI who undertook
cognitive debrief interviews on the paper version before it
was uploaded). However, the time frames for delivery of the
study meant that a fuller in-depth cognitive interviewing and
face validity exercise could not be undertaken.
Unfortunately, we do not know the lapse of time
between the administration of the questionnaire and the
administration of immunoglobulin. It is possible that
proximity to receiving Ig treatment may have influenced
the “severity” of participants responses. Everyone who
participated was currently receiving Ig treatment at the
Table 8 Domain Summary Statistics by Age Group (<60/≥60)
Domain/Age Group
0 = No Ig Treatment
Burden,
100 = Maximum Ig
Treatment Burden
Number
of Non-
Missing
Scores
Domain Score Number (%)
with Not
Applicable
Responses
Number
(%) of
Missing
Scores
P value
***
Bonferroni
Significant
= (p≤0.005)
Mean
(Standard
Deviation)
95% CI Median Interquartile
Range
Range
1. Time Burden 379 27.4 (22.7) 25.2–29.7 25 12.5–43.8 0.0–100.0 0 (0%) 16 (4%) P<0.005***
● <60 292 29.6 (22.3) 27.1–32.2 25 12.5–43.8 0.0–100.0 0 (0%) 14 (5%)
● ≥60 87 20.1 (22.7) 15.4–24.9 12.5 0.0–31.2 0.0–87.5 0 (0%) 2 (2%)
2. Organization and
Planning Burden
373 21.8 (19.3) 19.8–23.7 15 5.0–35.0 0.0–100.0 86 (23%) 22 (6%) P>0.005
● <60 287 22.9 (19.3) 20.7–25.2 20 5.0–35.0 0.0–100.0 64 (22%) 19 (6%)
● ≥60 86 17.9 (18.6) 14.0–21.8 10 5.0–30.0 0.0–85.0 22 (26%) 3 (3%)
3. Leisure/Social Burden 373 30.1 (21.1) 28.0–32.2 25 15.0–45.0 0.0–90.0 0 (0%) 22 (6%) P>0.005
● <60 289 30.7 (20.3) 28.4–33.0 25 15.0–45.0 0.0–90.0 0 (0%) 17 (6%)
● ≥60 84 28.1 (23.6) 23.0–33.2 25 10.0–45.0 0.0–90.0 0 (0%) 5 (6%)
4. Interpersonal
Relationship Burden
375 24.2 (22.2) 21.9–26.4 16.7 8.3–41.7 0.0–100.0 53 (14%) 20 (5%) P<0.005***
● <60 288 26.0 (22.2) 23.4–28.6 25 8.3–41.7 0.0–91.7 39 (14%) 18 (6%)
● ≥60 87 18.0 (20.9) 13.6–22.4 16.7 0.0–25.0 0.0–100.0 14 (16%) 2 (2%)
5. Employment and
Education Burden
383 18.3 (26.5) 15.6–20.9 0 0.0–33.3 0.0–100.0 189 (49%) 12 (3%) P<0.005***
● <60 295 22.1 (27.9) 18.9–25.2 8.3 0.0–33.3 0.0–100.0 120 (41%) 11 (4%)
● ≥60 88 5.6 (15.6) 2.3–8.8 0 0.0–0.0 0.0–83.3 69 (78%) 1 (1%)
6. Travel Burden 380 12.7 (19.4) 10.8–14.6 0 0.0–20.0 0.0–100.0 209 (55%) 15 (4%) P>0.005
● <60 297 13.7 (20.1) 11.5–16.0 5 0.0–20.0 0.0–100.0 148 (50%) 9 (3%)
● ≥60 83 9.0 (16.1) 5.5–12.4 0 0.0–10.0 0.0–85.0 61 (73%) 6 (7%)
7. Consequences of
Treatment Burden
376 28.4 (16.1) 26.8–30.1 25 16.7–37.5 0.0–79.2 0 (0%) 19 (5%) P>0.005
● <60 288 28.9 (16.3) 27.0–30.8 25 16.7–41.7 0.0–79.2 0 (0%) 18 (6%)
● ≥60 88 27.0 (15.3) 23.8–30.2 25 16.7–37.5 0.0–70.8 0 (0%) 1 (1%)
8. Emotional Burden 376 29.6 (25.5) 27.1–32.2 25 8.3–50.0 0.0–100.0 0 (0%) 19 (5%) P<0.005***
● <60 289 31.9 (25.7) 28.9–34.8 25 8.3–50.0 0.0–100.0 0 (0%) 17 (6%)
● ≥60 87 22.2 (23.1) 17.4–27.1 16.7 0.0–33.3 0.0–83.3 0 (0%) 2 (2%)
Global Ig Treatment
Burden
374 38.2 (25.5) 35.7–40.8 25 25.0–50.0 0.0–100.0 0 (0%) 21 (5%) P>0.005
● <60 286 39.5 (24.1) 36.7–42.3 50 25.0–50.0 0.0–100.0 0 (0%) 20 (7%)
● ≥60 88 34.1 (29.2) 28.0–40.2 25 0.0–50.0 0.0–100.0 0 (0%
(0%)
1 (1%)
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time of survey completion and we have reported the mean,
median and range for the amount of years spent on Ig
therapy.
It was not possible for us to achieve the sample size needed
to undertake the psychometric tests (in the study timeframe)
without widening recruitment beyond the UK to include the
additional nine countries. However, the sample size of patients
for each country (eg, average 12 IV respondents per country)
may not sufficiently reflect the whole population and we
cannot exclude the role of recruitment bias in our findings.
Firstly, it is possible that if we had recruited Ig participants via
other means (eg, directly from hospitals rather than from the
membership of local patient organisations), then differences in
treatment burden may be observed, although it is currently
unclear howmembership of a patient organisationwould affect
the burden of treatment (eg, the need to travel to hospital).
Secondly, it was not possible to mitigate possible bias
between countries. However, everyone included met the
same inclusion and exclusion criteria and whilst there were
some differences in the observed IgBoT-35 domain values
by country, none were significant.
Despite these limitations, the study has resulted in the
largest PID survey ever conducted across Europe and Canada
to date and, whilst further validation and psychometric testing
is required, it has also generated the first-ever Ig specific
burden of treatment measure for this patient group, which is
already translated and ready to use across 10 countries. Our
research has also started to identifywhere possible Ig treatment
burden may be present, and whilst further research is needed,
our findings may help facilitate more personalised and mini-
mally disruptive treatment for the PID patient which is a key
goal of healthcare delivery. This international surveywould not
have been possible without the involvement of a combined and
multidisciplinary team (comprising academic, industry, and
PPI partners) and in particular the support of IPOPI and its
NMOs to encourage and support recruitment. This information
may be helpful to other teams seeking to undertake cross-
cultural research in the field of patient-reported outcome mea-
surement which is increasingly desired.
Conclusion
The IgBoT-35 appears to be a reliable, patient-generated ques-
tionnaire. A further survey is currently being undertaken in a
new sample of US patients to test the conceptual model of the
measure and undertake further tests of reliability and validity.
Overall, treatment burden from both IVIg and SCIg appears
lower than expected which is reassuring for both PID patients
and their clinical teams. However, individual differences such
as age and gender appeared to affect treatment burden and
intravenous delivery of Igmay seem to have a bigger impact on
patients’ work, social and leisure aspects. Therefore, ensuring
the patient has the possibility of choosing the administration
route of their treatment in collaboration with their treating
physician is warranted to ensure that the treatment has the
lesser impact on the patient’s daily life. The IgBoT-35 ques-
tionnaire, when used in research and clinical practice may help
to better understand the support needs of PID patients facing Ig
treatment choices and identify the ways in which Ig treatment
modality is impacting upon the patient’s lives. This should
enable the most appropriate personalized Ig treatment plan to
be implemented more quickly, thus minimising the treatment
burden for the PID patient.
Data Sharing Statement
The datasets generated during and/or analysed during the
current study are not publicly available because they contain
information that could compromise research participant
Table 9 IgBoT-35 Domain Values by Location (Home versus Hospital Treatment)
Domain Name
0 = No Ig Treatment Burden,
100 = Maximum Ig Treatment Burden
Mean Value in Hospital Based Mean Value in Home Based t-test P-value
***Bonferroni
Significant
Time 30.5 26.6 P>0.005
Organisation/Planning 24.4 21.0 P>0.005
Leisure/Social 38.1 27.9 P≤0.005***
Interpersonal Relationship 28.4 22.9 P>0.005
Employment/Education 31.8 14.6 P≤0.005***
Travel 28.8 8.4 P≤0.005***
Consequences of Treatment 33.2 27.2 P>0.005
Emotional 28.7 29.9 P>0.005
Overall/Global 42.1 37.2 P>0.005
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privacy/consent. However, some data may be available from
the corresponding author on reasonable request.
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